# KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

> **NCT05938725** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Kyverna Therapeutics** · enrollment: 6 (actual)

## Conditions studied

- Lupus Nephritis
- Lupus Nephritis - World Health Organization (WHO) Class III
- Lupus Nephritis - WHO Class IV

## Interventions

- **BIOLOGICAL:** KYV-101 anti-CD19 CAR-T cell therapy
- **DRUG:** Standard lymphodepletion regimen

## Key facts

- **NCT ID:** NCT05938725
- **Lead sponsor:** Kyverna Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-28
- **Primary completion:** 2026-08
- **Final completion:** 2027-08
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05938725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05938725, "KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05938725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*